Biogen Newsroom

Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating

Moomoo NewsOct 1 03:32 ET

Baird Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294

Moomoo NewsSep 25 18:32 ET

BMO Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $260

Moomoo NewsSep 25 09:33 ET

A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $225 to $300

Moomoo NewsSep 25 09:03 ET

Maintaining Hold on Biogen Amid Uncertain Efficacy and Competitive SLE Market

TipRanksSep 25 06:27 ET

Buy Rating Affirmed for Biogen on Promising Phase 3 Results and Strategic Development Plans for Lupus Drug Dapi

TipRanksSep 24 08:48 ET

Biogen Is Maintained at Neutral by Wedbush

Dow JonesSep 23 10:04 ET

Biogen Analyst Ratings

BenzingaSep 23 09:54 ET

Wedbush Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $205

Moomoo NewsSep 23 09:32 ET

Wedbush Trims Price Target on Biogen to $205 From $210, Keeps Neutral Rating

MT NewswiresSep 23 06:46 ET

Biogen Analyst Ratings

BenzingaSep 19 09:17 ET

RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $292

Moomoo NewsSep 19 07:33 ET

RBC Capital Keeps Their Buy Rating on Biogen (BIIB)

TipRanksSep 19 06:47 ET

Biogen Analyst Ratings

BenzingaSep 9 11:28 ET

BMO Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $260

Moomoo NewsSep 5 07:31 ET

Optimistic Buy Rating for Biogen on Strategic Cost-Cutting and Growth Asset Prioritization

TipRanksSep 5 07:01 ET

Needham Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $285

Moomoo NewsSep 4 06:31 ET

Biogen Analyst Ratings

BenzingaSep 4 06:26 ET

Biogen's Upward Trajectory: A Buy Rating on Alzheimer's and Pipeline Progress

TipRanksSep 4 06:20 ET

Oppenheimer Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $270

Moomoo NewsSep 3 08:31 ET